Drug profile · INN
spironolactone
ALDACTONE
spironolactone (ALDACTONE) is a mineralocorticoid receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — spironolactone
- US status
- approved
- Class
- Cardiovascular system (C03)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.89
Quick answer
spironolactone (ALDACTONE) is a mineralocorticoid receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Mineralocorticoid receptor antagonist
Primary target: Mineralocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is spironolactone?
spironolactone (ALDACTONE) is a mineralocorticoid receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for spironolactone?
ALDACTONE is a marketed brand name for spironolactone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of spironolactone?
spironolactone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.